Pharmacology: Obutin exerts direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscles.
It exhibits no blocking effects at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects).
Obutin relaxes bladder smooth muscle in patients with conditions characterized by involuntary bladder contractions. Cystometric studies have demonstrated that Obutin increases bladder capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle and delays the intial desire to void. It decreases urgency and the frequency of both incontinent episodes and voluntary urination.
Obutin was well tolerated in patients administered the drug in controlled studies of 30 days' duration and in uncontrolled studies in which some of the patients received Obutin for 2 years.
For the relief of pollakiuria & uroclepsia caused by uninhibited or reflex neurogenic bladder (nocturnal enuresis, diurnal enuresis, night pollakiuria).
Adults: Usual Dose: One 5-mg tab 2-3 times a day. Maximum Recommended Dose: One 5-mg tab 4 times a day.
Children (>5 years): Usual Dose: One 5-mg tab 2 times a day.
Maximum Recommended Dose: One 5-mg tab 3 times a day.
Closed-angle glaucoma, obstruction of the gastrointestinal tract, paralytic ileus, intestinal atony, toxic megacolon, obstructive uropathy, unstable cardiovascular status in acute hemorrhage.
General: When administered in the presence of high environmental temperature, can cause heat prostration (due to decreased sweating).
Effects on the Ability to Drive or Operate Machinery: Obutin may produce drowsiness. The patient should be cautioned regarding activities requiring mental alertness eg, operating a motor vehicle or other machinery or performing hazardous work while taking Obutin.
Use in pregnancy: The safety of Obutin administered to women who are or who may become pregnant has not been established. Therefore, Obutin should not be given to pregnant women unless in the judgement of the physician, the probable clinical benefits outweigh the possible hazards.
Use in pregnancy: The safety of Obutin administered to women who are or who may become pregnant has not been established. Therefore, Obutin should not be given to pregnant women unless in the judgement of the physician, the probable clinical benefits outweigh the possible hazards.
Dry mouth, decreased sweating, urinary hesitance and retention, amblyopia, palpitations, tachycardia, cycloplegia, mydriasis, drowsiness, dizziness, insomnia, nausea, constipation, swelling, impotence, suppression of lactation, severe allergic reaction, rash and drug hypersensitivity.
Alcohol or other sedative drugs may enhance drowsiness caused by Obutin.
G04BD04 - oxybutynin ; Belongs to the class of urinary antispasmodics.
Obutin tab 5 mg
100 × 10's
Sign Out
